Skip to main content

Articles

Page 5 of 31

  1. The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL pat...

    Authors: Manman Deng, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, Govind Bhagat, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, William W. L. Choi, Jooryung Huh…

    Citation: Journal of Hematology & Oncology 2020 13:148

    Content type: Letter to the Editor

    Published on:

  2. Oncological care was largely derailed due to the reprioritisation of health care services to handle the initial surge of COVID-19 patients adequately. Cancer screening programmes were no exception in this repr...

    Authors: Avinash G. Dinmohamed, Matteo Cellamare, Otto Visser, Linda de Munck, Marloes A. G. Elferink, Pieter J. Westenend, Jelle Wesseling, Mireille J. M. Broeders, Ernst J. Kuipers, Matthias A. W. Merkx, Iris D. Nagtegaal and Sabine Siesling

    Citation: Journal of Hematology & Oncology 2020 13:147

    Content type: Letter to the Editor

    Published on:

  3. The epidemiology of esophageal cancer (EC) can elucidate its causes and risk factors and help develop prevention strategies. We aimed to provide an overview of the burden, trends, and risk factors of EC in Chi...

    Authors: Si Yang, Shuai Lin, Na Li, Yujiao Deng, Meng Wang, Dong Xiang, Grace Xiang, Shuqian Wang, Xianghua Ye, Yi Zheng, Jia Yao, Zhen Zhai, Ying Wu, Jingjing Hu, Huafeng Kang and Zhijun Dai

    Citation: Journal of Hematology & Oncology 2020 13:146

    Content type: Research

    Published on:

  4. Drug-loaded nanoparticles have established their benefits in the fight against multiple myeloma; however, ligand-targeted nanomedicine has yet to successfully translate to the clinic due to insufficient effica...

    Authors: David T. Omstead, Franklin Mejia, Jenna Sjoerdsma, Baksun Kim, Jaeho Shin, Sabrina Khan, Junmin Wu, Tanyel Kiziltepe, Laurie E. Littlepage and Basar Bilgicer

    Citation: Journal of Hematology & Oncology 2020 13:145

    Content type: Research

    Published on:

  5. Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-rib...

    Authors: Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong and Tian Zhang

    Citation: Journal of Hematology & Oncology 2020 13:144

    Content type: Review

    Published on:

  7. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13045-020-00969-0.

    Authors: Chun-Hua Wei, Gang Wu, Qian Cai, Xi-Can Gao, Fan Tong, Rui Zhou, Rui-Guang Zhang, Ji-Hua Dong, Yu Hu and Xiao- Rong Dong

    Citation: Journal of Hematology & Oncology 2020 13:142

    Content type: Retraction Note

    Published on:

    The original article was published in Journal of Hematology & Oncology 2017 10:125

  8. Glioblastoma (GBM) is a universally lethal tumor with frequently overexpressed or mutated epidermal growth factor receptor (EGFR). NADPH quinone oxidoreductase 1 (NQO1) and glutathione-S-transferase Pi 1 (GSTP...

    Authors: Kecheng Lei, Xiaoxia Gu, Alvaro G. Alvarado, Yuhong Du, Shilin Luo, Eun Hee Ahn, Seong Su Kang, Bing Ji, Xia Liu, Hui Mao, Haian Fu, Harley I. Kornblum, Lingjing Jin, Hua Li and Keqiang Ye

    Citation: Journal of Hematology & Oncology 2020 13:141

    Content type: Research

    Published on:

  9. IKZF1 belongs to the IKAROS family of transcription factors, and its deletion/mutation frequently affects acute lymphoblastic leukemia. In acute myeloid leukemia, IKZF1 deletion has been demonstrated recurrent, b...

    Authors: Xiang Zhang, Xuewu Zhang, Xia Li, Yunfei Lv, Yanan Zhu, Jinghan Wang, Jie Jin and Wenjuan Yu

    Citation: Journal of Hematology & Oncology 2020 13:140

    Content type: Letter to the Editor

    Published on:

  10. Acute myeloid leukemia (AML) is a heterogeneous and complex disease, and treatments for this disease have not been curative for the majority of patients. In younger patients, internal tandem duplication of FLT3 (

    Authors: Lindsey T. Brinton, Pu Zhang, Katie Williams, Daniel Canfield, Shelley Orwick, Steven Sher, Ronni Wasmuth, Larry Beaver, Casey Cempre, Jordan Skinner, Matthew Cannon, Mukul Govande, Bonnie Harrington, Amy Lehman, John C. Byrd, Rosa Lapalombella…

    Citation: Journal of Hematology & Oncology 2020 13:139

    Content type: Rapid communication

    Published on:

  12. Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and child...

    Authors: Jorge E. Cortes, Marcos de Lima, Hervé Dombret, Elihu H. Estey, Sergio A. Giralt, Pau Montesinos, Christoph Röllig, Adriano Venditti and Eunice S. Wang

    Citation: Journal of Hematology & Oncology 2020 13:137

    Content type: Review

    Published on:

  13. Cancer stem cells (CSCs) represent a tumor subpopulation responsible for tumor metastasis and resistance to chemo- and radiotherapy, ultimately leading to tumor relapse. As a consequence, the detection and era...

    Authors: Julia López de Andrés, Carmen Griñán-Lisón, Gema Jiménez and Juan Antonio Marchal

    Citation: Journal of Hematology & Oncology 2020 13:136

    Content type: Review

    Published on:

  14. Pediatric myelodysplastic syndrome (PMDS) is a very rare and still poorly characterized disorder. In this work, we identified novel potential targets of PMDS by determining genes with aberrant expression, whic...

    Authors: Lorena Zubovic, Silvano Piazza, Toma Tebaldi, Luca Cozzuto, Giuliana Palazzo, Viktoryia Sidarovich, Veronica De Sanctis, Roberto Bertorelli, Tim Lammens, Mattias Hofmans, Barbara De Moerloose, Julia Ponomarenko, Martina Pigazzi, Riccardo Masetti, Cristina Mecucci, Giuseppe Basso…

    Citation: Journal of Hematology & Oncology 2020 13:135

    Content type: Letter to the Editor

    Published on:

  15. High-grade serous carcinoma (HGSC) is the most prevalent and aggressive subtype of ovarian cancer. The large degree of clinical heterogeneity within HGSC has justified deviations from the traditional one-size-...

    Authors: Meinusha Govindarajan, Christoph Wohlmuth, Matthew Waas, Marcus Q. Bernardini and Thomas Kislinger

    Citation: Journal of Hematology & Oncology 2020 13:134

    Content type: Review

    Published on:

  16. Patients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have h...

    Authors: Julio García-Suárez, Javier de la Cruz, Ángel Cedillo, Pilar Llamas, Rafael Duarte, Víctor Jiménez-Yuste, José Ángel Hernández-Rivas, Rodrigo Gil-Manso, Mi Kwon, Pedro Sánchez-Godoy, Pilar Martínez-Barranco, Blanca Colás-Lahuerta, Pilar Herrera, Laurentino Benito-Parra, Adrián Alegre, Alberto Velasco…

    Citation: Journal of Hematology & Oncology 2020 13:133

    Content type: Research

    Published on:

  17. Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45–55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of pati...

    Authors: Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia-Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo…

    Citation: Journal of Hematology & Oncology 2020 13:132

    Content type: Research

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:34

  18. SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B c...

    Authors: Guido Lancman, John Mascarenhas and Michal Bar-Natan

    Citation: Journal of Hematology & Oncology 2020 13:131

    Content type: Letter to the Editor

    Published on:

  19. Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve as targets in precise therapy. Using ne...

    Authors: Yunzhen Qian, Yitao Gong, Zhiyao Fan, Guopei Luo, Qiuyi Huang, Shengming Deng, He Cheng, Kaizhou Jin, Quanxing Ni, Xianjun Yu and Chen Liu

    Citation: Journal of Hematology & Oncology 2020 13:130

    Content type: Review

    Published on:

  20. Increasing evidence suggests that high-density lipoprotein (HDL) may play a role in cancer development. We tested the hypothesis that low HDL levels are associated with increased risk of cancer.

    Authors: Kasper Mønsted Pedersen, Yunus Çolak, Stig Egil Bojesen and Børge Grønne Nordestgaard

    Citation: Journal of Hematology & Oncology 2020 13:129

    Content type: Research

    Published on:

  21. Acute myeloid leukemia (AML) is a fatal hematopoietic malignancy and has a prognosis that varies with its genetic complexity. However, there has been no appropriate integrative analysis on the hierarchy of dif...

    Authors: Junqing Wu, Yanyu Xiao, Jie Sun, Huiyu Sun, Haide Chen, Yuanyuan Zhu, Huarui Fu, Chengxuan Yu, Weigao E., Shujing Lai, Lifeng Ma, Jiaqi Li, Lijiang Fei, Mengmeng Jiang, Jingjing Wang, Fang Ye…

    Citation: Journal of Hematology & Oncology 2020 13:128

    Content type: Research

    Published on:

  23. The inhibition of the DNA damage response (DDR) pathway in the treatment of cancer has recently gained interest, and different DDR inhibitors have been developed. Among them, the most promising ones target the...

    Authors: Andrea Ghelli Luserna di Rorà, Claudio Cerchione, Giovanni Martinelli and Giorgia Simonetti

    Citation: Journal of Hematology & Oncology 2020 13:126

    Content type: Review

    Published on:

  24. B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including ant...

    Authors: Bo Yu, Tianbo Jiang and Delong Liu

    Citation: Journal of Hematology & Oncology 2020 13:125

    Content type: Review

    Published on:

  25. Extrachromosomal circular DNA was recently found to be particularly abundant in multiple human cancer cells, although its frequency varies among different tumor types. Elevated levels of extrachromosomal circu...

    Authors: Yuanliang Yan, Guijie Guo, Jinzhou Huang, Ming Gao, Qian Zhu, Shuangshuang Zeng, Zhicheng Gong and Zhijie Xu

    Citation: Journal of Hematology & Oncology 2020 13:124

    Content type: Review

    Published on:

  26. Conventional therapeutic approaches for tumor angiogenesis, which are primarily focused on the inhibition of active angiogenesis to starve cancerous cells, target the vascular endothelial growth factor signali...

    Authors: Young Sun Choi, Hyeonha Jang, Biki Gupta, Ji-Hak Jeong, Yun Ge, Chul Soon Yong, Jong Oh Kim, Jong-Sup Bae, Im-Sook Song, In-San Kim and You Mie Lee

    Citation: Journal of Hematology & Oncology 2020 13:123

    Content type: Research

    Published on:

  27. Recent evidence suggests that resistance to CD19 chimeric antigen receptor (CAR)-modified T cell therapy may be due to the presence of CD19 isoforms that lose binding to the single-chain variable fragment (scF...

    Authors: Runxia Gu, Fang Liu, Dehui Zou, Yingxi Xu, Yang Lu, Bingcheng Liu, Wei Liu, Xiaojuan Chen, Kaiqi Liu, Ye Guo, Xiaoyuan Gong, Rui Lv, Xia Chen, Chunlin Zhou, Mengjun Zhong, Huijun Wang…

    Citation: Journal of Hematology & Oncology 2020 13:122

    Content type: Research

    Published on:

  28. Non-coding RNAs (ncRNAs) have been the focus of many studies over the last few decades, and their fundamental roles in human diseases have been well established. Transfer RNAs (tRNAs) are housekeeping ncRNAs t...

    Authors: Mengqian Yu, Bingjian Lu, Jisong Zhang, Jinwang Ding, Pengyuan Liu and Yan Lu

    Citation: Journal of Hematology & Oncology 2020 13:121

    Content type: Review

    Published on:

  29. Critically ill patients diagnosed with COVID-19 may develop a pro-thrombotic state that places them at a dramatically increased lethal risk. Although platelet activation is critical for thrombosis and is respo...

    Authors: Si Zhang, Yangyang Liu, Xiaofang Wang, Li Yang, Haishan Li, Yuyan Wang, Mengduan Liu, Xiaoyan Zhao, Youhua Xie, Yan Yang, Shenghui Zhang, Zhichao Fan, Jianzeng Dong, Zhenghong Yuan, Zhongren Ding, Yi Zhang…

    Citation: Journal of Hematology & Oncology 2020 13:120

    Content type: Research

    Published on:

  30. Tumor metastasis accounts for the majority of cancer-related deaths; it is therefore important to develop preclinical models that faithfully recapitulate disease progression. Here, we generated paired organoid...

    Authors: He Li, Weixing Dai, Xi Xia, Renjie Wang, Jing Zhao, Lingyu Han, Shaobo Mo, Wenqiang Xiang, Lin Du, Guangya Zhu, Jingjing Xie, Jun Yu, Nan Liu, Mingzhu Huang, Jidong Zhu and Guoxiang Cai

    Citation: Journal of Hematology & Oncology 2020 13:119

    Content type: Letter to the Editor

    Published on:

  31. Synthetic lethality is a lethal phenomenon in which the occurrence of a single genetic event is tolerable for cell survival, whereas the co-occurrence of multiple genetic events results in cell death. The main...

    Authors: Win Topatana, Sarun Juengpanich, Shijie Li, Jiasheng Cao, Jiahao Hu, Jiyoung Lee, Kenneth Suliyanto, Diana Ma, Bin Zhang, Mingyu Chen and Xiujun Cai

    Citation: Journal of Hematology & Oncology 2020 13:118

    Content type: Review

    Published on:

  32. N6-methyladenosine (m6A) is the most abundant mRNA modification and is catalyzed by the methyltransferase complex, in which methyltransferase-like 3 (METTL3) is the sole catalytic subunit. Accumulating evidence i...

    Authors: Chengwu Zeng, Wanxu Huang, Yangqiu Li and Hengyou Weng

    Citation: Journal of Hematology & Oncology 2020 13:117

    Content type: Review

    Published on:

  33. High mobility group box 1 (HMGB1) is a non-histone chromatin-associated protein widely distributed in eukaryotic cells and is involved in DNA damage repair and genomic stability maintenance. In response to sti...

    Authors: Shumin Wang and Yi Zhang

    Citation: Journal of Hematology & Oncology 2020 13:116

    Content type: Editorial

    Published on:

  34. Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethaso...

    Authors: Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder…

    Citation: Journal of Hematology & Oncology 2020 13:115

    Content type: Research

    Published on:

  35. Eph receptors and the corresponding Eph receptor-interacting (ephrin) ligands jointly constitute a critical cell signaling network that has multiple functions. The tyrosine kinase EphA2, which belongs to the f...

    Authors: Ta Xiao, Yuhang Xiao, Wenxiang Wang, Yan Yan Tang, Zhiqiang Xiao and Min Su

    Citation: Journal of Hematology & Oncology 2020 13:114

    Content type: Review

    Published on:

  37. ETV4 is one of the ETS proteins overexpressed in prostate cancer (PC) as a result of recurrent chromosomal translocations. In human prostate cell lines, ETV4 promotes migration, invasion, and proliferation; ho...

    Authors: Irene Cosi, Annamaria Pellecchia, Emanuele De Lorenzo, Eugenio Torre, Michela Sica, Gabriella Nesi, Rosario Notaro and Maria De Angioletti

    Citation: Journal of Hematology & Oncology 2020 13:112

    Content type: Research

    Published on:

  38. Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed treatment in solid tumor oncology. ...

    Authors: Basit Salik, Mark J. Smyth and Kyohei Nakamura

    Citation: Journal of Hematology & Oncology 2020 13:111

    Content type: Review

    Published on:

  39. In recent years, cancer immunotherapy based on immune checkpoint inhibitors (ICIs) has achieved considerable success in the clinic. However, ICIs are significantly limited by the fact that only one third of pa...

    Authors: Rong Tang, Jin Xu, Bo Zhang, Jiang Liu, Chen Liang, Jie Hua, Qingcai Meng, Xianjun Yu and Si Shi

    Citation: Journal of Hematology & Oncology 2020 13:110

    Content type: Review

    Published on:

  40. Noncoding RNAs (ncRNAs) are a large segment of the transcriptome that do not have apparent protein-coding roles, but they have been verified to play important roles in diverse biological processes, including d...

    Authors: Yu-Meng Sun and Yue-Qin Chen

    Citation: Journal of Hematology & Oncology 2020 13:109

    Content type: Review

    Published on:

  41. Multiple Myeloma (MM) is a hematological malignancy with genomic heterogeneity and poor survival outcome. Apart from the central role of genetic lesions, epigenetic anomalies have been identified as drivers in...

    Authors: Samrat Roy Choudhury, Cody Ashby, Ruslana Tytarenko, Michael Bauer, Yan Wang, Shayu Deshpande, Judith Den, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Faith E. Davies, Frits van Rhee, Gareth J. Morgan and Brian A. Walker

    Citation: Journal of Hematology & Oncology 2020 13:108

    Content type: Research

    Published on:

  42. As crucial antigen presenting cells, dendritic cells (DCs) play a vital role in tumor immunotherapy. Taking into account the many recent advances in DC biology, we discuss how DCs (1) recognize pathogenic anti...

    Authors: Yingying Wang, Ying Xiang, Victoria W. Xin, Xian-Wang Wang, Xiao-Chun Peng, Xiao-Qin Liu, Dong Wang, Na Li, Jun-Ting Cheng, Yan-Ning Lyv, Shu-Zhong Cui, Zhaowu Ma, Qing Zhang and Hong-Wu Xin

    Citation: Journal of Hematology & Oncology 2020 13:107

    Content type: Review

    Published on:

  43. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Dan Jin, Jiwei Guo, Yan Wu, Jing Du, Lijuan Yang, Xiaohong Wang, Weihua Di, Baoguang Hu, Jiajia An, Lingqun Kong, Lei Pan and Guoming Su

    Citation: Journal of Hematology & Oncology 2020 13:106

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2019 12:135

  44. Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of ...

    Authors: Yu Chen, Min Gao, Zhaoqin Huang, Jinming Yu and Xiangjiao Meng

    Citation: Journal of Hematology & Oncology 2020 13:105

    Content type: Review

    Published on:

  45. Enhancer of zeste homolog 2 (EZH2) is enzymatic catalytic subunit of polycomb repressive complex 2 (PRC2) that can alter downstream target genes expression by trimethylation of Lys-27 in histone 3 (H3K27me3). ...

    Authors: Ran Duan, Wenfang Du and Weijian Guo

    Citation: Journal of Hematology & Oncology 2020 13:104

    Content type: Review

    Published on:

  46. Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI). PROTACs are potentially superior to con...

    Authors: Yonghan He, Sajid Khan, Zhiguang Huo, Dongwen Lv, Xuan Zhang, Xingui Liu, Yaxia Yuan, Robert Hromas, Mingjiang Xu, Guangrong Zheng and Daohong Zhou

    Citation: Journal of Hematology & Oncology 2020 13:103

    Content type: Review

    Published on:

  47. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Sha-Sha Cheng, Guan-Jun Yang, Wanhe Wang, Chung-Hang Leung and Dik-Lung Ma

    Citation: Journal of Hematology & Oncology 2020 13:102

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:26

  48. MicroRNAs (miRNAs) play important roles in cell proliferation, differentiation, and survival and may be useful for acute myeloid leukemia (AML) diagnosis and prognosis. In this study, we defined a novel miRNA,...

    Authors: Yan Jia, Wei Liu, Hui-En Zhan, Xiao-Ping Yi, Hui Liang, Qi-Li Zheng, Xin-Ya Jiang, Hai-Yan Zhou, Liang Zhao, Xie-Lan Zhao and Hui Zeng

    Citation: Journal of Hematology & Oncology 2020 13:101

    Content type: Letter to the Editor

    Published on:

  49. Both inflammasomes and autophagy have important roles in the intracellular homeostasis, inflammation, and pathology; the dysregulation of these processes is often associated with the pathogenesis of numerous c...

    Authors: Chaeuk Chung, Wonhyoung Seo, Prashanta Silwal and Eun-Kyeong Jo

    Citation: Journal of Hematology & Oncology 2020 13:100

    Content type: Review

    Published on:

  50. The cyclin-dependent kinase 7 (CDK7) subunit of TFIIH regulates RNA polymerase-II-based transcription and promotes tumor progression. However, the mechanisms involved in CDK7-mediated immune evasion are unclea...

    Authors: Jian Wang, Ruiguang Zhang, Zhenyu Lin, Sheng Zhang, Yaobing Chen, Jing Tang, Jiaxin Hong, Xiaoshu Zhou, Yan Zong, Yingzhuo Xu, Rui Meng, Shuangbing Xu, Li Liu, Tao Zhang, Kunyu Yang, Xiaorong Dong…

    Citation: Journal of Hematology & Oncology 2020 13:99

    Content type: Research

    Published on:

JHO logo
Submit manuscript

Follow

Annual Journal Metrics

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us